Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > SABCS 2019 > Long-Term Study Results > Sensory peripheral neuropathy after taxane treatment is not uncommon

Sensory peripheral neuropathy after taxane treatment is not uncommon

Conference
SABCS 2019
    Peripheral neuropathy post-taxane chemotherapy has been shown to be significantly more prevalent in a real-world cohort than in historical trials, according to the results of a single center study. Symptoms and subsequent decrease in quality of life (QoL) persisted well beyond a typical follow-up period. As rates of chemotherapy-induced peripheral neuropathy and the effect on QoL are important when counselling and consenting patients for treatment and when considering survivorship, higher rates of paclitaxel-associated sensory peripheral neuropathy in diabetic patients may assist decision-making on adjuvant chemotherapy regimens.

    Until recently, limited data was available beyond 3 years on sensory peripheral neuropathy and its effects on QoL in a non-clinical trial population. Blackley et al. aimed to assess the rates of persistent neuropathy in patients with early breast cancer who were treated with adjuvant taxanes and its effect on QoL [1]. This was done by identifying patients from hospital medical records who had received adjuvant taxane-containing regimens for early breast cancer over a 10-year period from 2007-2017 and inviting them to participate. Data was collected at a single time point using the EORTC Quality of Life (QLQ30) and Chemotherapy-Induced Peripheral Neuropathy (CIPN20) questionnaires.

    It was found that QoL scores were lower in patients with moderate or severe sensory peripheral neuropathy: median global QoL scaled score was 50 versus 75 in patients with no or mild sensory peripheral neuropathy (P=0.0062). Increasing sensory peripheral neuropathy score was associated with lower QoL score controlling for time from chemotherapy. The severity of sensory peripheral neuropathy decreased over time, which suggests there may be recovery in some patients beyond 2 years. However, it was pointed out that this analysis was limited by small patient numbers and did not reach statistical significance.

    The researchers also found that diabetes mellitus was the only significant comorbid factor associated with higher sensory peripheral neuropathy scores (P=0.03) and that paclitaxel was associated with higher rates of sensory peripheral neuropathy than docetaxel (adjusted mean scaled score in diabetic patients was 46.7 vs 20.9; P=0.001). Also, the interaction of paclitaxel with diabetes mellitus was significant, independent of other sensory peripheral neuropathy risk factors and time from chemotherapy (P=0.02). Early cessation of chemotherapy did not predict for late onset or persistent sensory peripheral neuropathy, although this was a very small retrospectively identified subgroup.

    1. Blackley EF, et al. P1-17-06. SABCS 2019.



    Posted on